Physician profile
Riaz Rassekh
NPI 1285674770
$12,444.46
in general payments reported to CMS, 2019-2025
43 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $2,216 · 2021: $2,278 · 2022: $1,635 · 2023: $1,441 · 2024: $1,832 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,360.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,386.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $951.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $907.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $823.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $681.11 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $640.06 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $590.21 | 2019-2022 | |
| Amgen INC. | $587.03 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.73 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $459.91 | 2019-2022 | |
| Abbvie INC. | $377.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $323.74 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Abbott Laboratories | $222.51 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $190.00 | 2020-2025 | Veozah |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riaz Rassekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.